LLMpediaThe first transparent, open encyclopedia generated by LLMs

CooperVision

Generated by GPT-5-mini
Note: This article was automatically generated by a large language model (LLM) from purely parametric knowledge (no retrieval). It may contain inaccuracies or hallucinations. This encyclopedia is part of a research project currently under review.
Article Genealogy
Parent: Bausch & Lomb Hop 3
Expansion Funnel Raw 82 → Dedup 9 → NER 7 → Enqueued 5
1. Extracted82
2. After dedup9 (None)
3. After NER7 (None)
Rejected: 2 (not NE: 2)
4. Enqueued5 (None)
Similarity rejected: 2
CooperVision
CooperVision
CooperVision · CC BY-SA 3.0 de · source
NameCooperVision
TypeSubsidiary
IndustryEyecare
Founded1980s
HeadquartersSan Ramon, California, United States
Key peopleWilliam J. Hickey Jr.
ProductsContact lenses, toric lenses, multifocal lenses, silicone hydrogel lenses
ParentThe Cooper Companies

CooperVision is a global manufacturer of contact lenses serving eye care professionals, patients, and optical retailers worldwide. The company operates within the medical-device sector alongside firms in ophthalmology and optical retail, supplying soft contact lenses, specialty lenses, and associated materials to markets in North America, Europe, Asia-Pacific, and Latin America. CooperVision's activities intersect with regulatory agencies, academic ophthalmology centers, and multinational corporations in the eyewear and health-care supply chain.

History

CooperVision's corporate lineage traces connections to earlier enterprises and mergers that involved executives and investors from Bausch + Lomb, Johnson & Johnson, Alcon, CIBA Vision, and Pfizer. Its expansion through the 1990s and 2000s paralleled consolidation trends affecting EssilorLuxottica, Novartis, Abbott Laboratories, and private equity firms such as Warburg Pincus and The Carlyle Group. Strategic acquisitions and capital investments were negotiated in boardrooms influenced by advisors from Morgan Stanley, Goldman Sachs, and JP Morgan Chase and reflected competitive responses to regulatory actions by the U.S. Food and Drug Administration, European Medicines Agency, and national health authorities in Japan and Australia. Leadership transitions involved executives with backgrounds at General Electric, 3M, Procter & Gamble, and academic affiliations with institutions like Harvard Medical School and Johns Hopkins University School of Medicine.

Products and Technology

The product portfolio includes daily disposable soft lenses, monthly silicone hydrogel lenses, toric lenses for astigmatism correction, and multifocal lenses for presbyopia, developed using polymer chemistries and surface treatments comparable to technologies from Alcon and Johnson & Johnson Vision. Material science collaborations and patents cite foundational work by researchers affiliated with Massachusetts Institute of Technology, Stanford University, Imperial College London, and University of California, Berkeley. Manufacturing processes integrate equipment and controls supplied by engineering firms such as Siemens, ABB Group, and Schneider Electric, and quality systems aligned with standards from International Organization for Standardization and notifications to agencies including the U.S. Food and Drug Administration. Distribution packages and retailer agreements reference partners in retail optics and e‑commerce like LensCrafters, Vision Express, Walgreens Boots Alliance, and Alibaba Group.

Manufacturing and Operations

CooperVision operates manufacturing sites and research facilities that interact with logistics providers such as DHL, UPS, and FedEx Corporation to serve markets overseen by trade organizations including AdvaMed and European Federation of Pharmaceutical Industries and Associations. Factory automation has employed robotics and process control platforms developed by firms like Fanuc, KUKA, and Rockwell Automation, while environmental and workplace safety programs reflect guidance from Occupational Safety and Health Administration and Environmental Protection Agency regulations. Supply-chain resilience strategies reference lessons from disruptions like the COVID-19 pandemic and geopolitical events involving China–United States relations and Brexit that affected global sourcing and manufacturing footprints.

Corporate Governance and Ownership

As a business unit, CooperVision is part of a corporate structure connected to public and private capital markets, with governance practices comparable to those at The Cooper Companies, Board of Directors, and auditor relationships similar to engagements by PricewaterhouseCoopers, Deloitte, KPMG, and Ernst & Young. Executive compensation and shareholder relations are informed by proxy advisory firms such as Institutional Shareholder Services and Glass Lewis, while corporate transactions have been scrutinized by regulators including the U.S. Securities and Exchange Commission and competition authorities like the European Commission Directorate‑General for Competition.

Market Presence and Competitors

CooperVision competes in global contact lens markets dominated by companies including Alcon, Johnson & Johnson Vision, Bausch + Lomb, and regional players linked to conglomerates like EssilorLuxottica and pharmaceutical groups such as Novartis. Market share dynamics reference reports from firms like McKinsey & Company, BCG, Deloitte, and Euromonitor International, and retail channels include optical chains such as Pearle Vision, Specsavers, and online retailers like Warby Parker and 1-800 Contacts. Competitive strategies reflect mergers and partnerships among multinational corporations and responses to reimbursement and formulary policies shaped by payers such as national health services in United Kingdom and Canada.

Research, Innovation, and Clinical Trials

Research programs have partnered with academic centers and hospitals including Moorfields Eye Hospital, Bascom Palmer Eye Institute, Wills Eye Hospital, and universities such as University of Oxford and University of Melbourne to conduct clinical evaluations of lens performance, comfort, and ocular health metrics. Clinical trial design and reporting align with guidelines from World Health Organization, CONSORT, and regulatory submissions to the U.S. Food and Drug Administration and national notified bodies in Germany and France. Innovation efforts draw on collaborations with biotech accelerators, venture capital firms like Sequoia Capital and Accel Partners, and standards bodies such as International Organization for Standardization for medical devices, while scholarly dissemination appears in journals like The Lancet, Ophthalmology (journal), and JAMA Ophthalmology.

Category:Contact lens manufacturers Category:Medical device companies of the United States